Track MeiraGTx Holdings plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MeiraGTx Holdings plc MGTX · Stock Open MeiraGTx Holdings plc in new tab

9.18 USD
P/E
11.03
EPS
0.87
P/B
4.19
ROE
72.17
Beta
1.07
Target Price
27.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
P/E11.03
EPS0.87
Book Value2.29
Price to Book4.19
Debt/Equity52.05
% Insiders16.272%
Growth
Revenue Growth86.09%
Estimates
Forward P/E-6.30
Forward EPS-1.53
Target Mean Price27.75

DCF valuation

Model fair value for MeiraGTx Holdings plc (MGTX)
Result
Sign in to run the valuation for MGTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus None · mean target 27.75 USD (low 16.00, high 50.00) · as of 11 Nov 2026
Low 16.00
Mean 27.75
High 50.00
Price 9.18
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

MeiraGTx Holdings plc Logo MeiraGTx Holdings plc Analysis (MGTX)

United States Health Care Official Website Stock

Is MeiraGTx Holdings plc a good investment? MeiraGTx Holdings plc (MGTX) is currently trading at 9.18 USD. Market analysts have a consensus price target of 27.75 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 11.03. This relatively low multiple may signal that MeiraGTx Holdings plc is undervalued compared to historical market norms.

Earnings Schedule: MeiraGTx Holdings plc is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -1.53.

Investor FAQ

Does MeiraGTx Holdings plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is MeiraGTx Holdings plc?

MeiraGTx Holdings plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of 0.87.

Company Profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Exchange Ticker
FRA (Germany) 328.F
NMS (United States) MGTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion